Teva
Biotech

Teva ends trial of one of original line-up of innovative meds

Teva has given up on a key trial of one of its original line-up of innovative medicines.
James Waldron Nov 2, 2026 9:22am
The cost of waiting What reaching clinical proof-of-concept sooner means for biotech cash burn

The cost of waiting: how early proof-of-concept shapes cash burn

Brought to you by Altasciences
FDA stop sign

Bright Minds seizure study on partial hold over toxicity in mice

Nov 2, 2026 8:43am
bid
Favicon Fierce Pharma

Karyopharm files Chapter 11 ahead of Ayrmid merger

Nov 2, 2026 10:46am
Brain scan neuroscience

Lower dose of Tiziana CD3 drug hits MS goal, unlike higher dose

Nov 2, 2026 8:37am
Completing steps towards success checkmark on cubes symbolizing progress

InventisBio’s ph. 3 psoriasis win yields competitive TYK2 data

Nov 2, 2026 6:30am
More News

When drug development gets personal

Oct 30, 2026 9:28am

Lilly International's Patrik Jonsson to retire—Chutes & Ladders

Oct 30, 2026 8:30am

Jazz's Actio buyout gives rise to Setara with $90M series A

Oct 30, 2026 6:30am

AstraZeneca cuts early-phase prostate cancer pipeline

Oct 30, 2026 5:03am